| human | Q5 |
| P10359 | IRIS UNIGE author ID | 38168 |
| P11718 | OPENBS author ID | 00703 |
| P496 | ORCID iD | 0000-0001-6691-8568 |
| P11597 | Padua Research Archive author ID | 33067 |
| P1153 | Scopus author ID | 7006770735 |
| P69 | educated at | University of Chicago | Q131252 |
| University of Parma | Q1758474 | ||
| P108 | employer | University of Brescia | Q1781263 |
| P734 | family name | Metra | Q37202925 |
| Metra | Q37202925 | ||
| Metra | Q37202925 | ||
| P735 | given name | Marco | Q17520955 |
| Marco | Q17520955 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q59684503 | Q59684503 |
| Q59683972 | A Case of a Fistula between Myxoma and a Branch of Right Coronary Artery |
| Q57158457 | A Critical Appraisal of Short-term Endpoints in Acute Heart Failure Clinical Trials |
| Q90767094 | A case of combined aortic bioprosthetic valve degeneration and patient-prosthesis mismatch during pregnancy: decision-making and implications after pregnancy |
| Q46133240 | A case of iatrogenic severe mitral regurgitation |
| Q41476569 | A combined clinical and biomarker approach to predict diuretic response in acute heart failure |
| Q38574443 | A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). |
| Q44909860 | A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). |
| Q87214700 | A drastic complex atheromatous aorta. A case report |
| Q40359671 | A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial |
| Q40150029 | A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure |
| Q91535526 | A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure |
| Q56958315 | A new educational program in heart failure drug development: the Brescia international master program |
| Q45091868 | A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score |
| Q59684591 | A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension |
| Q37583316 | A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure |
| Q40777024 | A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. |
| Q57735077 | ABSTRACTS |
| Q34560910 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolo |
| Q59684372 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary |
| Q22306351 | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation |
| Q59684386 | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary |
| Q58973291 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European S |
| Q58973358 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolog |
| Q51137889 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolo |
| Q44238823 | ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary |
| Q51935524 | ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiolog |
| Q56626176 | ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committ |
| Q97636716 | ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19 |
| Q41082948 | ANMCO/SIC Consensus Document: cardiology networks for outpatient heart failure care |
| Q30248251 | ANMCO/SIC Consensus document: The heart failure network: organization of outpatient care |
| Q43564400 | Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study |
| Q39174869 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study |
| Q54249241 | Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. |
| Q94456080 | Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology |
| Q35139964 | Acute decompensated heart failure update |
| Q34622692 | Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure |
| Q37794561 | Acute heart failure clinical drug development: from planning to proof of activity to phase III. |
| Q57422643 | Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial |
| Q48137492 | Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study |
| Q48047763 | Acute heart failure in the young: Clinical characteristics and biomarker profiles |
| Q47339351 | Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome |
| Q91864026 | Acute heart failure: More questions than answers |
| Q57911301 | Acute heart failure: lessons learned, roads ahead |
| Q37764139 | Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy |
| Q44876292 | Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results |
| Q90789256 | Adrenomedullin in heart failure: pathophysiology and therapeutic application |
| Q36811824 | Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology |
| Q56381075 | Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology |
| Q50224329 | Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. |
| Q57911440 | Age, Clinical Characteristics and Outcomes of Patients With Acute Decompensated Heart Failure: Insights from the PROTECT Trial |
| Q24645066 | Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond |
| Q28084239 | Agents with vasodilator properties in acute heart failure: how to design successful trials |
| Q38219915 | Amino acids and derivatives, a new treatment of chronic heart failure? |
| Q87059183 | An unusual case of myocardial infarction |
| Q59684153 | Anaemia and heart failure |
| Q35252704 | Anemia and heart failure: a cause of progression or only a consequence? |
| Q54744617 | Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. |
| Q38044305 | Anticoagulation in heart failure: current status and future direction |
| Q93332917 | April 2020 at a glance: epidemiology, prevention, and biomarkers |
| Q57628639 | Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry |
| Q53667788 | Arrhythmias and cardiomyopathy: when arrhythmias come first. |
| Q53105002 | Ascending Aortic Dimensions in Hypertensive Subjects: Reference Values for Two-Dimensional Echocardiography. |
| Q37721628 | Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medi |
| Q59683896 | Assessment of Congestion in Acute Heart Failure: When Simplicity Does Not Go Along With Accuracy |
| Q30585648 | Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure |
| Q43724908 | Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort |
| Q90824396 | Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry |
| Q98729687 | Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study |
| Q58102786 | Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF) |
| Q38382604 | Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure |
| Q97654124 | Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk? |
| Q101239072 | August 2020 at a glance: focus on neurohormonal antagonists and electrolytes |
| Q45237005 | Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study |
| Q35631382 | Beta-blockade in heart failure: selective versus nonselective agents |
| Q44182274 | Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol |
| Q36723828 | Beta-blocker therapy of heart failure: an update |
| Q44648434 | Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol |
| Q35934100 | Beta-blockers in heart failure: are pharmacological differences clinically important? |
| Q38689033 | Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). |
| Q92184681 | Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure |
| Q38721084 | Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction |
| Q48741780 | Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. |
| Q38279998 | Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. |
| Q38387228 | Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure |
| Q44760161 | Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox |
| Q51870022 | CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. |
| Q95313317 | CARDIOVASCULAR DEATH RISK IN RECOVERED MID-RANGE EJECTION FRACTION HEART FAILURE: INSIGHTS FROM CARDIOPULMONARY EXERCISE TEST |
| Q104289204 | COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation |
| Q94930355 | COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease |
| Q104289515 | COVID-19 in Heart Transplant Recipients: A Multicenter Analysis of the Northern Italian Outbreak |
| Q88680746 | Can Carbohydrate Antigen-125 Be a New Biomarker to Guide Heart Failure Treatment?: The CHANCE-HF Trial |
| Q37845856 | Can we improve the treatment of congestion in heart failure? |
| Q37873812 | Can we prevent or treat renal dysfunction in acute heart failure? |
| Q37893011 | Can we prevent or treat renal dysfunction in chronic heart failure? |
| Q90701695 | Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) |
| Q102056079 | Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure |
| Q92609671 | Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry |
| Q37738591 | Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial |
| Q100950986 | Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes |
| Q30249193 | Cardiorenal Interactions |
| Q91626886 | Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study |
| Q37801830 | Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure |
| Q59684329 | Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure |
| Q102060755 | Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2 |
| Q43077326 | Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) progr |
| Q93257544 | Centralization of the ST elevation myocardial infarction care network in the Lombardy region during the COVID-19 outbreak |
| Q41534613 | Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? |
| Q57628798 | Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial |
| Q41141233 | Characteristics and mid-term follow-up of a single-center population affected by Tako-Tsubo cardiomyopathy |
| Q94561399 | Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy |
| Q44655145 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial |
| Q38516856 | Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact? |
| Q59683905 | Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial |
| Q41244849 | Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). |
| Q94595785 | Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors |
| Q45043359 | Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure |
| Q88683541 | Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry |
| Q90327393 | Clinical Role of CA125 in Worsening Heart Failure: A BIOSTAT-CHF Study Subanalysis |
| Q90844518 | Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study |
| Q40521709 | Clinical efficacy of ibopamine in patients with chronic heart failure |
| Q30655054 | Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome |
| Q38115936 | Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document |
| Q38212254 | Clinical pharmacology of inodilators |
| Q92300601 | Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology |
| Q64088256 | Clinical profiles in acute heart failure: an urgent need for a new approach |
| Q40696115 | Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia |
| Q37941602 | Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. |
| Q38430272 | Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations |
| Q37710255 | Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward |
| Q59684333 | Clinical trials update from the World Congress of Cardiology 2006 |
| Q91662964 | Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission |
| Q59684546 | Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function |
| Q38391668 | Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure |
| Q46274105 | Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial |
| Q38960401 | Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial |
| Q43704234 | Comparative effects of atrial and ventricular stimulation on morbidity and mortality in patients with sinus node disease |
| Q91100862 | Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction |
| Q34213067 | Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial |
| Q40450951 | Competing Risk of Cardiac Status and Renal Function During Hospitalization for Acute Decompensated Heart Failure. |
| Q91239044 | Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment |
| Q96127128 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) |
| Q37340293 | Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design |
| Q41541649 | Coronary Artery Disease and High Altitude: Unresolved Issues |
| Q40086592 | Coronary angiography in worsening heart failure: determinants, findings and prognostic implications |
| Q97540982 | Coronavirus 2019 Disease (COVID-19), Systemic Inflammation, and Cardiovascular Disease |
| Q100756278 | Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience |
| Q98782673 | Coronavirus disease 2019 and cardiovascular implications |
| Q101212432 | Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure |
| Q57298652 | Corrigendum to 'Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology' [Eur |
| Q88006590 | Corrigendum: Carnosine: Potential aid for diabetes and cardiovascular disease |
| Q35939051 | Current guidelines in the pharmacological management of chronic heart failure |
| Q38009708 | Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure |
| Q39156298 | Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial |
| Q92337448 | December 2019 at a glance: economic burden, co-morbidities, and prognosis |
| Q47724698 | Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. |
| Q43177885 | Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment e |
| Q39252375 | Design of the RELAXin in acute heart failure study. |
| Q40280356 | Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study |
| Q40313672 | Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure |
| Q38078064 | Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. |
| Q59684572 | Diagnosis of acute myocardial infarction by indium-111 antimyosin antibodies and correlation with the traditional techniques for the evaluation of extent and localization |
| Q59684606 | Diagnostic accuracy of rest-exercise first pass ventriculography with a fast single crystal gamma camera in detecting coronary artery disease |
| Q100407018 | Differences in biomarkers and molecular pathways according to age for patients with HFrEF |
| Q38905200 | Different types of tricuspid flail: Case reports and review of the literature |
| Q96688735 | Direct oral anticoagulants across the heart failure spectrum: the precision medicine era |
| Q90426717 | Direct oral anticoagulants for the treatment of left ventricular thrombus - a new indication? A meta-summary of case reports DOACs in left ventricular thrombosis |
| Q102064021 | Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results |
| Q89610330 | Distinct Pathological Pathways in Patients With Heart Failure and Diabetes |
| Q46015607 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance. |
| Q35810391 | Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. |
| Q38449925 | Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. |
| Q42190292 | Dopamine receptors in the stellate ganglion of the dog. |
| Q29392189 | Dopaminergic Drugs in Congestive Heart Failure |
| Q57628365 | Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation |
| Q99559141 | Drug development in oncology and devices-lessons for heart failure drug development and approval? a review |
| Q34148325 | Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study |
| Q39289569 | Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study |
| Q110902535 | ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up |
| Q46275793 | EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). |
| Q46414626 | EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). |
| Q38490345 | Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. |
| Q39269611 | Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study |
| Q44129824 | Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial |
| Q59683933 | Echocardiographic Evaluation of Aortic Atheromas in Patients With Aortic Stenosis |
| Q49701306 | Echocardiographic elastic properties of ascending aorta and their relationship with exercise capacity in patients with non-ischemic dilated cardiomyopathy. |
| Q41499507 | Echocardiographic evaluation in subjects with α1-Antitrypsin deficiency |
| Q59683887 | Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis: A case-control study |
| Q47675107 | Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study |
| Q38374099 | Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency |
| Q44264874 | Effect of carvedilol and metoprolol on the mode of death in patients with heart failure |
| Q38809793 | Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial |
| Q28242547 | Effect of nesiritide in patients with acute decompensated heart failure |
| Q34647669 | Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial |
| Q34646866 | Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes |
| Q46413006 | Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study |
| Q42844470 | Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure |
| Q43205980 | Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD stud |
| Q41416657 | Effectiveness of MitraClip therapy in patients with refractory heart failure |
| Q92750766 | Effects of Serelaxin in Patients with Acute Heart Failure |
| Q59683995 | Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms |
| Q103042553 | Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study |
| Q54263746 | Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. |
| Q49822657 | Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients. |
| Q41859441 | Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials |
| Q46450527 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. |
| Q31094492 | Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). |
| Q41728379 | Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure. |
| Q48063656 | Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. |
| Q40086861 | Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure |
| Q37184401 | Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF |
| Q92319251 | Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis |
| Q37240303 | Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF |
| Q44615512 | Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial |
| Q59684531 | Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy |
| Q85342202 | Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms |
| Q34655367 | Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials |
| Q57911473 | Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction |
| Q48795012 | Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. |
| Q49917375 | Effects of transcatheter aortic valve implantation on ascending aorta wall elastic properties: Tissue Doppler imaging and strain Doppler echocardiography study☆. |
| Q53072344 | Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. |
| Q44693672 | Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus |
| Q54369041 | Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations. |
| Q90754486 | EkoSonic Endovascular System for patients with acute pulmonary embolism and contraindication to systemic fibrinolysis |
| Q92424609 | Elastic aortic properties in cystic fibrosis adults without cardiovascular risk factors: A case-control study |
| Q48933146 | Elastic aortic properties in patients with X syndrome. |
| Q91575353 | Elastic properties of ascending aorta and ventricular-arterial coupling in women with previous pregnancy complicated by HELLP syndrome |
| Q59130735 | Elastic properties of the ascending aorta in patients with rheumatoid arthritis |
| Q51321183 | Elastic properties of the ascending aorta in patients with α1-antitrypsin deficiency (Z homozygotes). |
| Q40411180 | Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects |
| Q100667339 | Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure |
| Q35252723 | Endocannabinoids and cardiovascular prevention: real progress? |
| Q93008806 | Endomyocardial fibrosis and myocardial infarction leading to diastolic and systolic dysfunction requiring transplantation |
| Q28744360 | Endothelial damage due to air pollution |
| Q26796330 | Endpoints in stem cell trials in ischemic heart failure |
| Q95940938 | Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock - A position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) |
| Q46490070 | Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. |
| Q39668972 | European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions |
| Q91802305 | European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure |
| Q59684000 | Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-Tumor Necrosis Factor-α Therapy |
| Q49710877 | Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. |
| Q92458947 | Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology |
| Q42657951 | Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). |
| Q34389554 | Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology |
| Q40419769 | Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure--Application of Metabolic Exercise Cardiac Kidney Indexes Score. |
| Q59684551 | Exercise hyperventilation chronic congestive heart failure, and its relation to functional capacity and hemodynamics |
| Q91540428 | Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction |
| Q31089116 | Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group |
| Q92893525 | Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure |
| Q89905181 | February 2020 at a glance: acute heart failure and cardio-oncology |
| Q102071856 | Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial |
| Q48742018 | Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. |
| Q44534256 | Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development |
| Q37086300 | Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation |
| Q92006987 | Focus on echocardiographic right ventricular strain analysis in cystic fibrosis adults without cardiovascular risk factors: a case-control study |
| Q45285185 | Functional and hemodynamic cardiac determinants of exercise capacity in patients with systolic heart failure |
| Q92361997 | Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction |
| Q92530871 | Genetic risk and atrial fibrillation in patients with heart failure |
| Q39827043 | Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). |
| Q93041565 | Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study |
| Q92233652 | Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis |
| Q39183951 | Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study |
| Q95303850 | Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction |
| Q57245141 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) |
| Q57245143 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) |
| Q33996248 | Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology |
| Q59684420 | Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca aguda. Versión resumida |
| Q57911354 | HETEROGENEITY IN EFFICACY OF ROLOFYLLINE USING A RISK-BASED EVALUATION IN PATIENTS HOSPITALIZED WITH ACUTE HEART FAILURE |
| Q110902540 | HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community |
| Q42914818 | Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function |
| Q57628656 | Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction† |
| Q100695375 | Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The positi |
| Q92925812 | Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations |
| Q56210548 | Heart failure |
| Q30241376 | Heart failure 2016: still more questions than answers |
| Q39332451 | Heart failure and anemia: Effects on prognostic variables. |
| Q93120436 | Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology |
| Q34248538 | Heart failure in elderly patients: distinctive features and unresolved issues |
| Q104074195 | Heart failure in the last year: progress and perspective |
| Q58587336 | Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study |
| Q90997007 | Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years |
| Q38343702 | Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). |
| Q90678010 | Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF |
| Q90841019 | Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines |
| Q47295399 | Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure |
| Q43021939 | Heart rate: a risk factor or an epiphenomenon? |
| Q53730055 | HeartFailureNews, new in EJHF. |
| Q30724401 | Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow? |
| Q49298261 | Hemodynamic advantage of combined administration of oral ibopamine and nitroprusside in patients with ischemic and idiopathic congestive cardiomyopathy. |
| Q42034936 | Hemodynamic effects of the intravenous administration of captopril in patients with chronic congestive heart failure |
| Q90377006 | Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial |
| Q50722046 | High-Sensitive Cardiac Troponin for Prediction of Clinical Heart Failure: Are We Ready for Prime Time? |
| Q47109768 | High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction |
| Q45960834 | High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. |
| Q89459313 | Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction |
| Q93046014 | Highlights in heart failure |
| Q101154195 | Highlights in valvular heart diseases |
| Q59684263 | Highlights of the 2009 Scientific Sessions of the European Society of Cardiology |
| Q38667877 | Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial |
| Q90671193 | Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality |
| Q38389044 | Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure |
| Q59684121 | Hyponatremia and Long-Term Outcomes in Chronic Heart Failure—An Observational Study From the Duke Databank for Cardiovascular Diseases |
| Q57911312 | Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction |
| Q38705811 | Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure |
| Q92853657 | Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study |
| Q99203155 | If it ain't broken, don't fix it (but if it is, make sure you know): Aortic valve interventions during LVAD implantation |
| Q91795490 | Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology |
| Q99561369 | Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction |
| Q91897493 | Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair |
| Q101578670 | Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study |
| Q38484871 | Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study |
| Q98614675 | Implications for the Care of Patients With COVID-19 and Inflammatory Myocardial Disease-Reply |
| Q110902422 | Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study |
| Q97535199 | Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF |
| Q59684561 | Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure |
| Q37653092 | Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity i |
| Q44199904 | In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry |
| Q96690460 | In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department |
| Q38559347 | In-hospital worsening heart failure |
| Q47660827 | In-hospital worsening heart failure in patients admitted for acute heart failure |
| Q41054061 | Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy |
| Q59684070 | Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study |
| Q38387597 | Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). |
| Q46616032 | Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial |
| Q43275402 | Inotrope therapy in acute heart failure: a critical review of clinical and scientific evidence for levosimendan in the context of traditional treatment |
| Q49044088 | Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. |
| Q59684266 | Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction |
| Q88151527 | Integrating electronic health records into the study of heart failure: promises and pitfalls |
| Q97560354 | Interaction between severe chronic kidney disease and acute kidney injury in predicting mortality after transcatheter aortic valve implantation: Insights from the Italian Clinical Service Project |
| Q57911475 | International Differences in Acute Heart Failure (AHF) Patients: Insight from the PROTECT Trial |
| Q39202662 | International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial |
| Q91482424 | Iron deficiency in heart failure |
| Q91367535 | Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects |
| Q104503455 | Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF |
| Q52662716 | Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. |
| Q90916930 | Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial |
| Q38211780 | Is there a role for ivabradine beyond its conventional use? |
| Q59684469 | Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly?☆ |
| Q50985608 | Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. |
| Q37399996 | Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? |
| Q38252811 | Ivabradine during cardiogenic shock: a clinical case and review of the literature |
| Q89461713 | January 2020 at a glance: translational medicine, predictors of outcome and treatments |
| Q99566858 | July 2020 at a glance: focus on imaging and cardiomyopathies |
| Q98172485 | June 2020 at a glance: focus on COVID-19, quality of life and comorbidities |
| Q52647058 | Kounis syndrome, a disease to know: Case report and review of the literature. |
| Q59684598 | Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure |
| Q59684451 | Left internal thoracic artery−radial artery composite grafts as the technique of choice for myocardial revascularization in elderly patients: a prospective randomized evaluation |
| Q48607648 | Left ventricular function in rheumatoid arthritis during anti-TNF-α treatment: a speckle tracking prospective echocardiographic study. |
| Q90483522 | Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry |
| Q26738701 | Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper |
| Q90586084 | Life-saving transcatheter aortic valve implantation for acute severe aortic regurgitation due to rheumatoid arthritis and complicated by cardiogenic shock |
| Q40168931 | Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. |
| Q46048899 | Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study |
| Q50061496 | Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. |
| Q46328569 | Long-term prognostic value of longitudinal strain of right ventricle in patients with moderate heart failure |
| Q36741159 | Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation |
| Q51083978 | Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. |
| Q39276578 | Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. |
| Q44732752 | Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial |
| Q46108704 | Lower endothelial progenitor cell number, family history of cardiovascular disease and reduced HDL-cholesterol levels are associated with shorter leukocyte telomere length in healthy young adults |
| Q92152168 | Macro- and microvascular functions in cystic fibrosis adults without cardiovascular risk factors: A case-control study |
| Q95940808 | Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology |
| Q101565465 | Management of acute coronary syndromes during the COVID-19 outbreak in Lombardy: The "macro-hub" experience |
| Q38835768 | Management of acute heart failure in elderly patients |
| Q59684397 | Managing heart failure in the very old |
| Q90706229 | March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis |
| Q44321712 | Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance |
| Q38779423 | Maternal endothelial function and vascular stiffness after HELLP syndrome: a case-control study |
| Q104691174 | Maternal hemodynamics, arterial stiffness and elastic aortic properties in twin pregnancy |
| Q59683943 | May 2015 at a glance |
| Q95940999 | May 2020 at a glance: ischaemic heart failure and sex-related differences |
| Q51792108 | Measurement of the myocardial performance index in ambulatory patients with heart failure: correlation with other clinical and echocardiographic parameters and independent prognostic value. |
| Q38906411 | Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Stud |
| Q46132455 | Mechanical circulatory supports for the treatment of advanced heart failure |
| Q52650688 | Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence. |
| Q63353224 | Medical Misinformation |
| Q91239767 | Medical Misinformation |
| Q91245901 | Medical Misinformation |
| Q94487233 | Medical Misinformation |
| Q95395168 | Medical Misinformation |
| Q95395174 | Medical Misinformation |
| Q95395183 | Medical Misinformation |
| Q61803697 | Medical Misinformation: Vet the Message! |
| Q63353223 | Medical Misinformation: Vet the Message! |
| Q95403127 | Medical Misinformation: Vet the Message! |
| Q67449200 | Medical misinformation: Vet the message! |
| Q64265319 | Medical misinformation: vet the message! |
| Q64285776 | Medical misinformation: vet the message! |
| Q91250637 | Medical misinformation: vet the message! |
| Q90753855 | Mega-trials in heart failure: effects of dilution in examination of new therapies |
| Q34337289 | Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. |
| Q44969617 | MicroRNAs relate to early worsening of renal function in patients with acute heart failure |
| Q35009114 | Micronutrient deficiencies an unmet need in heart failure |
| Q49954326 | Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. |
| Q40173081 | Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. |
| Q49349456 | Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. |
| Q100426389 | MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry |
| Q51361659 | Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: is it still an exclusion criterion? |
| Q28084842 | Mode of Death After Acute Heart Failure Hospitalization - A Clue to Possible Mechanisms |
| Q87488986 | Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure |
| Q44183566 | Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry |
| Q47631869 | Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison |
| Q40689763 | N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatme |
| Q40691890 | N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure |
| Q43210407 | Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release |
| Q59684079 | Need for Ongoing Anti Arrhythmic Drugs After Ablation of Atrial Fibrillation. Review |
| Q89768306 | Negotiating renal dysfunction when treating patients with heart failure |
| Q38915487 | Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials |
| Q48903573 | Neurohormonal activation in acute heart failure: results from VERITAS. |
| Q43911771 | New and old beta-blockers in the treatment of heart failure |
| Q92521109 | New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold |
| Q88052505 | New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel |
| Q38955252 | New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment |
| Q34375466 | New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes |
| Q57911318 | Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction |
| Q35252676 | Non-compaction of the ventricular myocardium |
| Q54265657 | Nonbacterial thrombotic endocarditis in pancreatic cancer. |
| Q38221514 | Noninvasive assessment of endothelial function: the classic methods and the new peripheral arterial tonometry |
| Q46802021 | Not time to RELAX in acute heart failure - Authors' reply |
| Q91349599 | November 2019 at a glance. Chronic and acute heart failure: from epidemiology to treatment |
| Q37578330 | Nuclear cardiology and heart failure |
| Q26744466 | Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health |
| Q26741764 | Nutritional Deficiency in Patients with Heart Failure |
| Q38226912 | Obstructive sleep apnoea-hypopnoea and arrhythmias: new updates |
| Q90978420 | October 2019 at a glance: epidemiology, prevention, and modes of death |
| Q59684476 | Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study |
| Q37923533 | Old and new intravenous inotropic agents in the treatment of advanced heart failure |
| Q100305798 | Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC-HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials |
| Q89610340 | Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF |
| Q48490798 | Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transpla |
| Q41074638 | Optimizing clinical use of biomarkers in high-risk acute heart failure patients |
| Q37455607 | Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology |
| Q36273107 | Pathophysiologic targets in the early phase of acute heart failure syndromes |
| Q38560109 | Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality |
| Q104735289 | Patient with heart failure: importance to treat valvular diseases |
| Q50862582 | Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. |
| Q92650036 | Percutaneous treatment of mitral regurgitation: looking for a final model |
| Q95925948 | Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results |
| Q57628379 | Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry |
| Q28740781 | Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF |
| Q59684404 | Pharmacokinetic and Pharmacodynamic Characteristics of β-Blockers: When Differences May Matter |
| Q59684518 | Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations |
| Q45266003 | Pharmacological therapy of chronic heart failure in the elderly |
| Q57396271 | Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group |
| Q43258001 | Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes |
| Q34471934 | Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance |
| Q59684351 | Plasma Homocysteine Levels and Late Outcome in Patients with Unstable Angina |
| Q40126626 | Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure |
| Q40311889 | Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure |
| Q41174254 | Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome |
| Q91137527 | Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets |
| Q59684245 | Postdischarge Assessment After a Heart Failure Hospitalization |
| Q48741948 | Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. |
| Q48367651 | Pre-eclampsia and heart failure: a close relationship |
| Q38397809 | Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. |
| Q38571973 | Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models |
| Q38440582 | Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospital |
| Q89119100 | Preoperative cardiac risks in noncardiac surgery: The role of coronary angiography |
| Q52653549 | Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. |
| Q35120857 | Prevention and management of chronic heart failure in patients at risk |
| Q40871982 | Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients |
| Q92045103 | Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure |
| Q99623580 | Prognostic Impact of Heart Failure History in Patients with Secondary Mitral Regurgitation Treated by MitraClip |
| Q92891515 | Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF |
| Q57911321 | Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion |
| Q41060281 | Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure |
| Q59684407 | Prognostic Value of Cardiopulmonary Exercise Variables in Chronic Heart Failure Patients With or Without Beta-Blocker Therapy |
| Q104569672 | Prognostic Value of Pre-operative Atrial Fibrillation in Patients with Secondary Mitral Regurgitation Undergoing MitraClip Implantation |
| Q44667311 | Prognostic evaluation in patients with heart failure |
| Q88652271 | Prognostic evaluation of the elastic properties of the ascending aorta in dilated cardiomyopathy |
| Q59684354 | Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a β-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial |
| Q46378481 | Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. |
| Q30961727 | Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. |
| Q38944593 | Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. |
| Q90895474 | Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation |
| Q31126055 | Prognostic significance of clinical, ergometric and coronarographic data in patients soon after myocardial infarction |
| Q40706188 | Prognostic value of RV isovolumic acceleration and tissue strain in moderate HFrEF. |
| Q45892581 | Prognostic value of indeterminable anaerobic threshold in heart failure. |
| Q90608282 | Prognostic value of right ventricular free wall longitudinal strain in a large cohort of outpatients with left-side heart disease |
| Q41603329 | Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure. |
| Q88160410 | Prognostic value of the absolute lymphocyte count in patients admitted for acute heart failure |
| Q50136187 | Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. |
| Q47281852 | Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure |
| Q96683828 | Publication Rates of Heart Failure Clinical Trials Remain Low |
| Q101212431 | Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study |
| Q59684537 | Pulmonary hypertension and systemic hypotension as limitations to exercise in chronic heart failure |
| Q50971792 | Quantitative analysis of right ventricular (RV) function with echocardiography in chronic heart failure with no or mild RV dysfunction: comparison with cardiac magnetic resonance imaging. |
| Q60691547 | Radial access for primary PCI: a change of paradigm |
| Q104467967 | Rate of venous thromboembolism and atrial fibrillation in a real-world case series of advanced cancer patients: the CaTEV Study |
| Q92293076 | Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failur |
| Q44008859 | Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. |
| Q46856112 | Rationale and design of the enoximone clinical trials program |
| Q38737940 | Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations |
| Q38496703 | Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em |
| Q50236171 | Red cell distribution width and chronic heart failure: prognostic role beyond echocardiographic parameters. |
| Q52364966 | Redefining biomarkers in heart failure. |
| Q57818756 | Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points |
| Q46072220 | Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. |
| Q90102473 | Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial |
| Q39305717 | Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. |
| Q37356318 | Relaxin, a pleiotropic vasodilator for the treatment of heart failure. |
| Q33873275 | Relaxin: review of biology and potential role in treating heart failure |
| Q37900203 | Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment |
| Q98302236 | Renal failure after trans-catheter aortic valve implantation |
| Q41280127 | Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction. |
| Q38440574 | Renal function trajectories and clinical outcomes in acute heart failure |
| Q59684028 | Renin-Angiotensin System Blockade and Worsening Renal Function in Heart Failure |
| Q38208139 | Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. |
| Q59684033 | Reply |
| Q100506481 | Reply: Explaining differing outcomes from the COAPT and MITRA-FR trials using disproportionate and proportionate secondary mitral regurgitation |
| Q85520362 | Reply: Mode of Death Prevention by Serelaxin |
| Q100413089 | Reply: Potential Mechanisms to Improve Heart Failure Clinical Trial Publication Rates |
| Q59684131 | Response to Letter Regarding Article, “Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure? The Role of Congestion and Its Interaction With Renal Function” |
| Q59684287 | Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article “The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy” |
| Q46689132 | Revisiting cardiac injury during acute heart failure: further characterization and a possible target for therapy |
| Q99406519 | Right ventricular deformation and right ventricular-arterial coupling in patients with heart failure due to severe aortic stenosis undergoing TAVI: long-term results |
| Q40428593 | Right ventricular thrombus and pulmonary thromboembolism/thrombosis in Behçet's disease: a case report |
| Q41377882 | Risk assessment for a high-altitude alpinist with coronary artery disease |
| Q59684082 | Risk following hospitalization in stable chronic systolic heart failure |
| Q40597015 | Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial |
| Q58333610 | Role of ?1- and ?2-adrenoceptor polymorphisms in heart failure: a case-control study |
| Q59684035 | Role of Aliskiren on Arterial Stiffness and Endothelial Function in Patients With Primary Hypertension |
| Q43115277 | Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure |
| Q46724107 | Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study |
| Q47660867 | Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology |
| Q48113549 | Role of different vascular approaches on transcatheter aortic valve implantation outcome: a single-center study |
| Q44231383 | Role of echocardiography on the diagnosis is ventricular dyssynchrony in patients selected for cardiac resynchronization |
| Q38534370 | Role of the old and new echocardiographic technologies in cardiac resynchronization therapy |
| Q42868532 | Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure |
| Q94466420 | ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes |
| Q92739984 | Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach |
| Q89148882 | Sacubitril/valsartan: from a large clinical trial to clinical practice |
| Q92687469 | Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study |
| Q30250344 | School and family-based interventions for promoting a healthy lifestyle among children and adolescents in Italy: a systematic review |
| Q98187815 | Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort |
| Q59684498 | Selective or nonselective β-adrenergic blockade in patients with congestive heart failure |
| Q50184234 | Self-expanding transcatheter aortic valve implantation for degenerated small Mitroflow bioprosthesis: early and midterm outcomes. |
| Q90011591 | September 2019 at a glance: focus on devices |
| Q101059839 | September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy |
| Q38570717 | Serelaxin a novel treatment for acute heart failure. |
| Q39160286 | Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial |
| Q37711521 | Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial |
| Q33845755 | Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study |
| Q34310960 | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial |
| Q91658875 | Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure |
| Q39183948 | Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study |
| Q31141404 | Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). |
| Q47886116 | Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis |
| Q30994514 | Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis |
| Q57487277 | Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption |
| Q39974993 | Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias |
| Q37714568 | Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study |
| Q45141283 | Sex-specific acute heart failure phenotypes and outcomes from PROTECT. |
| Q59684361 | Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET |
| Q46457716 | Signature of circulating microRNAs in patients with acute heart failure |
| Q98657530 | Sinus Node Dysfunction in a Young Patient With COVID-19 |
| Q47662912 | Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. |
| Q34164006 | Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions |
| Q59684140 | Six-year prognosis of diabetic patients with coronary artery disease |
| Q88711497 | Sleep-disordered Breathing in Heart Failure - Current State of the Art |
| Q96954240 | Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology |
| Q38012596 | Soluble guanylate cyclase: a potential therapeutic target for heart failure |
| Q102131335 | Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure |
| Q37382704 | Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). |
| Q38896990 | Subclinical cardiac involvement in Crohn's disease and ulcerative colitis: an echocardiographic case-control study |
| Q44657198 | Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade |
| Q40424551 | Symptoms in patients with heart failure are prognostic predictors: insights from COMET. |
| Q46833198 | Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? |
| Q57911393 | TAILORING THERAPY IN ACUTE HEART FAILURE: CAN BIOMARKERS DISTINGUISH RESPONDERS FROM NON-RESPONDERS? |
| Q46340977 | Tachycardia after a heart failure hospitalization: another piece of the puzzle? |
| Q59683965 | Tako-tsubo cardiomyopathy in two sisters: a chance finding or familial predisposition? |
| Q100502955 | Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week |
| Q48631794 | Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients. |
| Q38171115 | Task force on: 'Early markers of atherosclerosis: influence of age and sex'. |
| Q46135672 | Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). |
| Q46548143 | The CORONA study |
| Q46029893 | The European CRT Survey: 1 year (9-15 months) follow-up results. |
| Q59683971 | The European Journal of Heart Failure now and in the years to come: a salutation from the incoming Editor-in-Chief |
| Q61650721 | The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume |
| Q64233578 | The New Heart Failure Association Definition of Advanced Heart Failure |
| Q47627618 | The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis |
| Q57911481 | The PROTECT In-Hospital Risk Model: 7-Day Outcome in Patients Hospitalized with Acute Heart Failure (AHF) and Renal Dysfunction |
| Q44840001 | The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction |
| Q28297684 | The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment |
| Q59684363 | The Safety of Amiodarone in Patients With Heart Failure |
| Q54295663 | The acute, chronic continuous after treatment and chronic intermittent with a variable therapeutic window (4 and 6 hours) hemodynamic effects induced with transdermal nitroglycerin in patients with congestive heart failure |
| Q91514528 | The brain-heart connection: a multiple sclerosis relapse presenting as Takotsubo Syndrome. A case report and literature review |
| Q90650182 | The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF |
| Q36711668 | The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF |
| Q92009745 | The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study |
| Q35252713 | The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia |
| Q59684040 | The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy |
| Q42924848 | The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study |
| Q40323189 | The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. |
| Q91537237 | The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure |
| Q31030359 | The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. |
| Q92267268 | The myth of 'stable' coronary artery disease |
| Q59684318 | The pathophysiology of acute heart failure—It is a lot about fluid accumulation |
| Q90453411 | The potential antiarrhythmic properties of sacubitril/valsartan: a case report |
| Q38117807 | The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure |
| Q44072950 | The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure |
| Q59684143 | The puzzle of kidney dysfunction in heart failure: an introduction |
| Q91662958 | The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach |
| Q46265973 | The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy |
| Q34580385 | The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. |
| Q34641418 | The role of the kidney in heart failure |
| Q49861415 | The role of type 2 diabetes mellitus on hypertensive-related aortic stiffness. |
| Q92290597 | The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular |
| Q46594720 | The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. |
| Q90844528 | The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology |
| Q112294353 | The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure |
| Q37876591 | Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions |
| Q28271500 | Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial) |
| Q73933337 | Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery |
| Q91991613 | Trajectories of Changes in Renal Function in Patients with Acute Heart Failure |
| Q98782674 | Transcatheter therapies for tricuspid valve regurgitation |
| Q38198876 | Transcatheter treatment of chronic mitral regurgitation with the MitraClip system: an Italian consensus statement. |
| Q57315294 | Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles |
| Q92214656 | Treatment of functional mitral regurgitation in chronic heart failure: can we get a 'proof of concept' from the MITRA-FR and COAPT trials? |
| Q59684297 | Treatment of heart failure in the elderly: never say it's too late |
| Q42745665 | Treatment of heart failure patients with inotropic drugs: beyond traditional agents |
| Q40922694 | Treatment of refractory heart failure. |
| Q92895515 | Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial |
| Q30837842 | Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry |
| Q57180759 | Treatments targeting inotropy |
| Q48450860 | Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. |
| Q59684149 | Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation |
| Q38637744 | Ultrasound evaluation of left ventricular and aortic fibrosis after pre-eclampsia |
| Q88160208 | Understanding worsening heart failure as a therapeutic target: another step forward? |
| Q60943112 | Updates in heart failure: what last year brought to us |
| Q46297230 | Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial |
| Q45984213 | Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. |
| Q59684510 | Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure |
| Q37858515 | Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents |
| Q59684414 | Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report |
| Q58615934 | Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure |
| Q100515388 | Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation |
| Q37355110 | Vasodilators in the treatment of acute heart failure: what we know, what we don't |
| Q53178592 | Ventilatory efficiency and the selection of patients for heart transplantation. |
| Q56967266 | Waist-to-hip ratio and mortality in heart failure |
| Q90349264 | Wellens' syndrome: a case report with atypical features |
| Q40964651 | Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies |
| Q57396169 | Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study |
| Q46750124 | Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. |
| Q43178428 | Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials |
| Q91844571 | [ANMCO/FADOI/SIAARTI/SIC/SIMG/SIMI/SIMEU consensus document: The clinical care pathway of acute heart failure patients from symptom onset to discharge from the emergency department] |
| Q83300321 | [Acute heart failure: clinical profiles and pathophysiology] |
| Q81829351 | [Beta-blockers in the treatment of heart failure] |
| Q53846042 | [Cardiopulmonary stress test for the evaluation of therapeutic results in heart failure. Maximal or submaximal test?] |
| Q87763447 | [Definition of acute heart failure] |
| Q81149455 | [Diagnosis and treatment of acute heart failure. Guidelines of the European Society of Cardiology] |
| Q74153718 | [Dilated cardiomyopathy: indication and role of invasive evaluation] |
| Q85266795 | [Efficacy of ACE-inhibitors in patients with recent myocardial infarction. Studies with zofenopril] |
| Q50932386 | [Evolution in coronary stenting: use of ticlopidine with and without oral anticoagulants]. |
| Q81761709 | [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure] |
| Q79335742 | [Guidelines on the management of stable angina pectoris: executive summary] |
| Q78491557 | [Heart failure: should treatment favor prognosis or quality of life? Opinion... in favor of prognosis] |
| Q89090481 | [Heart rate and outcome in patients with acute and chronic heart failure] |
| Q60439514 | [Insulin-resistance and cardiovascular risk] |
| Q79746125 | [Plasma brain natriuretic peptide levels in the diagnostic and prognostic assessment of patients with heart failure. Pros] |
| Q85266803 | [Role of nutrition in heart failure patients] |
| Q92032879 | [The COMMANDER-HF trial] |
| Q37749829 | n-3 PUFAs and cardiovascular disease prevention |
| Q27008175 | Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic |
Search more.